AbbVie’s Skyrizi sustains clinical and endoscopic outcomes in ulcerative colitis for up to three years
AbbVie will present 20 inflammatory bowel disease research abstracts at UEG Week, Oct. 17-20, 2026, in Barcelona. Skyrizi maintained clinical and endoscopic improvements in ulcerative colitis for up to three years; Rinvoq sustained Crohn's disease outcomes for approximately four years. Real-world findings linked switch